This randomized, placebo-controlled, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6807952. Patients will receive multiple weekly subcutaneous doses of RO6870952. The anticipated time on study treatment is 8 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
45
Unnamed facility
Chula Vista, California, United States
Unnamed facility
Cincinnati, Ohio, United States
Safety: Incidence of adverse events
Time frame: 8 weeks
Blood concentrations of RO6807952
Time frame: 8 weeks
Effect of RO6807952 on Hemoglobin HbA1c level
Time frame: 8 weeks
Effect of RO6807952 on glucose level
Time frame: 8 weeks
Change in meal tolerance test
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.